Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 26.27% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 32.0% YoY) and the FY2025 annual result came in at $1.1 billion, up 29.66% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.1 billion in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2026 to a low of $247.0 million in Q1 2022.
• A 5-year average of $654.0 million and a median of $646.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity rose 24.04% — and 2024, when it soared 86.83%.
• Tracing CPRX's Liabilities and Shareholders Equity over 5 years: stood at $375.6 million in 2022, then grew by 25.15% to $470.1 million in 2023, then soared by 81.11% to $851.4 million in 2024, then gained by 29.66% to $1.1 billion in 2025, then advanced by 3.95% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.